← back to search

Angelo Sangiovanni

University of Campania "Luigi Vanvitelli" · IT
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Hepatitis C virus research, and Liver Disease and Transplantation.
h-index
48
citations
10,421
works
322
NIH funding
primary concept
Medicine
email

Recent publications

Modified Charlson Comorbidity Index to Improve Management of Patients with Hepatocellular Carcinoma: A Step Towards Multiparametric Approach.
2026cited by 0position: contributordoi
Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular Carcinoma.
2026cited by 0position: contributordoi
Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma.
2025cited by 3position: contributordoi
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma
JAMA Surgery 2024cited by 36position: middledoi
An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infection
Nature Communications 2024cited by 13position: middledoi
Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy
Scientific Reports 2024cited by 8position: middledoi
Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma.
2024cited by 4position: contributordoi
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib.
2024cited by 2position: contributordoi
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
The Lancet Oncology 2023cited by 181position: middledoi
A 3-year course of bulevirtide monotherapy may cure HDV infection in patients with cirrhosis
Journal of Hepatology 2023cited by 29position: middledoi
A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
2023cited by 25position: contributordoi
Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy.
2023cited by 13position: contributordoi
Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection.
2023cited by 11position: contributordoi
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
2022cited by 70position: contributordoi
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
2022cited by 59position: contributordoi
Non-Oncological Radiotherapy: A Review of Modern Approaches
Journal of Personalized Medicine 2022cited by 14position: middledoi
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis
Gut 2021cited by 96position: middledoi
Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC.
2021cited by 17position: contributordoi
Reshape and secure HCC managing during COVID-19 pandemic: A single centre analysis of four periods in 2020 versus 2019.
2021cited by 7position: contributordoi
An Unprecedented Challenge: The North Italian Gastroenterologist Response to COVID-19.
2021cited by 0position: contributordoi
Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis
Journal of Hepatology 2020cited by 55position: firstdoi
The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy.
2020cited by 53position: contributordoi
Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
2020cited by 45position: contributordoi
An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma.
2020cited by 22position: contributordoi
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy.
2019cited by 14position: contributordoi
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma
Oncotarget 2018cited by 97position: middledoi
Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules
Journal of Hepatology 2017cited by 257position: middledoi
A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection
Gut 2015cited by 128position: middledoi
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration
Gut 2014cited by 75position: middledoi
Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage Cirrhosis
Gastroenterology 2013cited by 225position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Massimo Iavarone · University of Milan13 papers (2013–2026) · 13 papers (2019–2026)Pietro Lampertico · Pitié-Salpêtrière Hospital8 papers (2019–2026) · 7 papers (2019–2026) · 6 papers (2019–2026)Josep M. Llovet · Mayo Clinic in Florida4 papers (2012–2015)Fabio Piscaglia · Ludwig-Maximilians-Universität München3 papers (2017–2024)Augusto Villanueva · NYU Langone Health3 papers (2013–2015)Scott L. Friedman · Mount Sinai Health System3 papers (2013–2015)Yujin Hoshida · WinnMed3 papers (2013–2015)Christoph Neumann‐Haefelin · University of Freiburg2 papers (2023–2023) · 2 papers (2013–2014)Laura Gramantieri · University of Ferrara2 papers (2018–2024)Farzaneh Moshiri · The Ohio State University2 papers (2018–2024)Alessandro Vitale · Presbyterian Hospital2 papers (2024–2026)Massimo Negrini · The Ohio State University2 papers (2018–2024)Silvia Sabbioni · University of Ferrara2 papers (2018–2024)Masahiro Kobayashi · Hokuto Hospital2 papers (2014–2015)Hiromitsu Kumada · Toranomon Hospital2 papers (2014–2015)Maria Paola Anolli · University of Milan2 papers (2022–2023)